# Title
Measurement O
of O
blood O
concentrations O
of O
FK506 B-Chemical
(tacrolimus) B-Chemical
and O
its O
metabolites O
in O
seven O
liver O
graft O
patients B-Species
after O
the O
first O
dose O
by O
h.p.l.c.-MS O
and O
microparticle O
enzyme O
immunoassay O
(MEIA). O

# Abstract
1. O
Blood O
and O
urine O
concentrations O
of O
the O
macrolide B-Chemical
immunosuppressant O
FK506 B-Chemical
and O
its O
metabolites O
were O
measured O
in O
seven O
orthotopic O
liver O
transplant O
patients B-Species
after O
the O
first O
oral O
dose O
of O
FK506 B-Chemical
(0.04 O
+ O
- O
0.02 O
mg O
kg-1) O
used O
as O
primary O
immunosuppressant. O
A O
specific O
h.p.l.c.-MS O
assay O
was O
used, O
allowing O
the O
measurement O
of O
parent O
drug O
and O
eight O
metabolites. O
Results O
were O
compared O
with O
those O
obtained O
using O
a O
microparticle O
enzyme O
immunoassay O
(MEIA). O
2. O
Blood O
drug O
concentrations O
were O
described O
by O
an O
open O
two O
compartment O
model O
with O
first-order O
absorption O
giving O
the O
following O
mean O
data: O
tmax: O
1.9 O
(h), O
Cmax: O
17.4 O
(microgram O
l-1), O
AUC: O
328.1 O
(microgram O
l-1 O
h), O
t1 O
2,1: O
0.74 O
(h). O
The O
terminal O
elimination O
half-life O
was O
estimated O
at O
about O
26 O
h O
using O
the O
h.p.l.c.-MS O
assay. O
3. O
The O
metabolites O
found O
in O
blood O
were O
demethyl-FK506 O
and O
demethyl-hydroxy-FK506, O
while O
in O
urine O
FK506 B-Chemical
and O
eight O
of O
its O
metabolites O
were O
detected. O